AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05412173 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Molnupiravir
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Study NCT05448430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation
Description: a new paradigm of high frequency repetitive transcranial magnetic stimulation
Study NCT04723810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
Study NCT05341622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Differentiated Box
Description: Patients will receive mailed FIT kits in a box with differentiated packaging
Study NCT05341622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Mail
Description: Patients will receive mailed FIT in a standard mailing envelope
Study NCT05341622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text
Description: Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.
Study NCT05341622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Text
Description: Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.
Study NCT06277843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Jacket
Description: In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention (Thermal Jacket) as a supplement of Kangaroo Mother Care (KMC).
Study NCT05341622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.
Study NCT05341622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Reminder
Description: Patients will not receive any mailed letter reminder to complete their FIT kit.
Study NCT05130554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XEN45 gel stent implantation
Description: The XEN45 gel implant is a collagen tube with a length of 6 mm and a diameter of 45 µm, which creates a new channel for drainage of aqueous humor by connecting the anterior chamber and the subconjunctival space. The implant is composed of porcine gelatin cross-linked with glutaraldehyde, and has good biocompatibility and tolerance.This treatment method has excellent safety and effectiveness in reducing the intraocular pressure of patients with open-angle glaucoma. At the same time, the operation is simple and safe.
Study NCT06192173 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous PFO closure
Description: Two kinds of interventional closure methods including DSA-guided and TEE-guided percutaneous intervention were performed on closure group.
Study NCT06293976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changes in the ventilator respiratory rate and tidal volume
Description: With the ventilator on volume control and Vt at 6 ml/kg of predicted body weight (PBW) (standard clinical practice), an end-expiratory occlusion of 30 seconds on the ventilator will be performed to search for intrinsic respiratory rate (RR). The set RR will be modified from 6 breaths per minute (bpm) below up to 6 bpm above the clinical RR in steps of 2 bpm every 1 minute (random order). The changes in RR described above will be repeated with Vt set at 5, 7 and 8 ml/kg PBW (random order). The steps described above will be aborted at any point if SpO2 drops below 85% for at least two minutes, mean arterial pressure drops below 60 mmHg, or plateau pressure >35 cmH2O.~If an intrinsic respiratory rate ≥8 bpm is present and P/F ratio is ≥150, it will be propose to the clinician to place the patient in pressure support at a level preferred by clinicians for 5 minutes. If the patient tolerates well, it will be propose to the clinician to maintain the patient in pressure support ventilation,
Study NCT05067309 — intervention group
Intervention type: DRUG
Intervention: Letrozole 2.5mg
Description: Missed abortion received letrozole then misoprostol
Study NCT05227092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D OPTIMIZED WMN MPRAGE
Description: * At the cervical level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 2D Sagittal PSIR / 3D MPRAGE and the 3D OPTIMIZED MPRAGE WMN data set with sagittal and axial acquisition.~* At the thoracic level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 3D MPRAGE and the 3D Sagittal OPTIMIZED MPRAGE WMN data set.
Study NCT05271500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser acupuncture
Description: gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks
Study NCT05271500 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: laser acupuncture
Description: gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks
Study NCT06287268 — intervention group
Intervention type: OTHER
Intervention: eltrombopag
Description: This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.
Study NCT06688448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dafodil prosthesis
Description: Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
Study NCT06688448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic Valve Replacement - Inspires Resilia prosthesis
Description: Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
Study NCT06708260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403, low dose
Description: ENN0403 capsules will be orally administered once a day for 12 weeks.
Study NCT06708260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403, high dose
Description: ENN0403 capsules will be orally administered once a day for 12 weeks.
Study NCT05317819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG20
Description: Treatment for hepatocellular carcinoma
Study NCT05317819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for hepatocellular carcinoma
Study NCT06500273 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cemacabtagene ansegedleucel
Description: An allogeneic CAR T cell therapy targeting CD19
Study NCT06500273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: A monoclonal antibody targeting CD52
Study NCT06500273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion
Study NCT06500273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion
Study NCT06500273 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Description: A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for lLBCL.
Study NCT06500273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Description: A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for lLBCL.
Study NCT06742190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Empasiprubart
Description: Intravenous infusion of empasiprubart
Study NCT06742190 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IVIG (Intravenous Immunoglobulin)
Description: Intravenous infusion of IVIg
Study NCT06742190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Empasiprubart-placebo
Description: A placebo resembling the empasiprubart treatment
Study NCT06742190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVIg-placebo
Description: A placebo resembling the IVIg treatment
Study NCT06744816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qutenza Patch
Description: Given topical
Study NCT06759116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ml saline)
Study NCT06759116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl group
Description: The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 50 mcg fentanyl)
Study NCT06759116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine group
Description: The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ug/kg dexmedetomidine not exceeding 100 ug (to be completed to 1mL with normal saline if needed). )
Study NCT06765278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Patients will receive an Interscalene brachial plexus block.
Study NCT06765278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior glenoid nerve block
Description: Patients will receive an anterior glenoid nerve block.
Study NCT06765278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: Patients will receive a pericapsular nerve group (PENG) block.
Study NCT06774261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenserine
Description: Phenserine is a next generation AChE inhibitor being developed for the treatment of AD. Unlike currently marketed AChE inhibitors, it has additional mechanisms of action that also include a mediating effect on cell death pathways and anti-amyloid activity, which may confer disease-modifying effects in people with AD.~Phenserine was originally identified and developed by the United States (U.S.) National Institute of Aging (NIA), part of the U.S National Institute of Health (NIH).~The study intervention will be open label. No blinding will be performed. Participants and site staff will, however, will be blinded to the results of the exosome and blood/CSF biomarker evaluations until the study is completed.
Study NCT06774261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil (Aricept®)
Description: The substance donepezil (under the brand name Aricept®) is a resale product. No additional manufacturing or labeling measures is necessary for this study.~The NIMP, donepezil will be available in 5 mg and 10 mg strengths (table 3) and will be dispensed by the local pharmacy at the hospital where the participant in the donepezil arm is included. We have based the use of donepezil as a treatment in the study on the original product from Pfizer, but it is also possible to use generic products of donepezil if this is what the local pharmacy has for dispensing. Participants randomized to treatment with donepezil will follow the treatment plan according to the patient information leaflet. . These tablets are approved for clinical use and comply with all relevant safety and efficacy standards.
Study NCT06772766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Ascending IV doses administered per protocol
Study NCT06772766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Ascending IV doses administered per protocol
Study NCT06774092 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study NCT06774950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-patient quality circle
Description: Intervention: (To be compared with standard care)~1. Interprofessionnal meeting per neighbourhood: (beforehand) Therapeutic patient education (TPE) training for healthcare professionals~2. Physician-patient quality circle t0 Group sessions (n= 3 to 6 patients) with doctor and therapeutic patient education specialist Clinical measurements - CM (incl. HbA1c, body composition, blood pressure). PROM evaluation questionnaires (EQ5D\&DIABQ)~3. Development of individualised T2D programme: with case manager~4. Quarterly follow-up: t3, t6, t9 months PROM follow-up (DIABQ\&PHQ9) +CM.~5. Evaluation of experience: t12 \& t18 months PREM\&PROM evaluation questionnaire +CM
Study NCT06774963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNCB74
Description: LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.
Study NCT06772389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Tutoring
Description: Peer tutoring is defined as individuals who are in a similar social group and are not professional teachers helping each other to learn and teach. For peer tutoring, the subject of EFM was grouped under 6 headings. The students in the Peer tutoring group were divided into groups of 6. The researcher explained a heading of the EFM subject to each of these 6 groups. Then, new groups were formed by taking one student from each group. In these new groups, each student explained his/her own subject to his/her peers.
Study NCT06773169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IAMABLE web-based app
Description: The Intervention Group will use the IAMABLE app for 4 months. IAMABLE users identify activities that they are having difficulty with because of their health problem and set goals they want to work toward. Self-management (SM) modules help them reach their goals, providing information and rehabilitation strategies about exercise, fall prevention, fatigue management, pain management, physical activity, and stress management. Users complete a self-assessment associated with each module, and receive tailored recommendations that guide them to access relevant module topics. Users create 7-day action plans using the strategies in the module to address their activity goals. Users receive automated notifications when it is time to evaluate action plans and activity goals, as well as weekly messages to remind them to engage with the app. Users have access to therapist support using the Ask a Therapist feature and receive individual consultations in response to queries about SM.
Study NCT06773169 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: General health information
Description: The Control Group will receive a monthly email with general health information (not specific to rehabilitation or chronic diseases) for 4 months. Topics will include Nutrition, Vision Care, Foot Care, Hearing, Skin Care and Oral Care. Each email will include an introduction to the topic and links for additional information.
Study NCT06772610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib group
Description: Ensartinib 200 mg, once daily, orally, for a continuous period of 2 years.
Study NCT06770608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: micro-needling with topical human actrapid insulin
Description: Micro-needling with topical application of 2ml of human actrapid insulin once monthly for 4 months
Study NCT06770608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro-needling with topical Platelet rich plasma
Description: Micro-needling with topical application of 2ml Platelet rich plasma once monthly for 4 months
Study NCT06773325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buzzy application
Description: Buzzy application during heel prick blood collection
Study NCT06770335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THE FATIGUE, LEARNING, AND MEMORY ENRICHMENT (FLaME) INTERVENTION - Full intervention
Description: A novel strategy-based cognitive rehabilitation intervention that can be delivered with or without cognitive fatigue management. Skills are targeted sequentially based on a developmental hierarchical model where cognitive fatigue can be addressed first, followed by adult-supported compensatory strategies, with independent use of strategies for specific impairments delivered only once these earlier levels have been addressed. The 'FLaME' program incorporates strategies that have been trialled and found successful in fatigue (e.g., pacing and activity scheduling) and cognitive rehabilitation (e.g., chunking, elaborative encoding techniques) interventions for children. The intervention address two key issues: 1) to deliver strategy-based cognitive rehabilitation as an alternative to prevailing drill-based approaches, and 2) to integrate fatigue management to improve feasibility and acceptability of cognitive rehabilitation. This arm include the full intervention.
Study NCT06770335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THE FATIGUE, LEARNING, AND MEMORY ENRICHMENT (FLaME) INTERVENTION - Cognitive rehabilitation only
Description: A novel strategy-based cognitive rehabilitation intervention that can be delivered with or without cognitive fatigue management. Skills are targeted sequentially based on a developmental hierarchical model where cognitive fatigue can be addressed first, followed by adult-supported compensatory strategies, with independent use of strategies for specific impairments delivered only once these earlier levels have been addressed. The 'FLaME' program incorporates strategies that have been trialled and found successful in fatigue (e.g., pacing and activity scheduling) and cognitive rehabilitation (e.g., chunking, elaborative encoding techniques) interventions for children. The intervention address two key issues: 1) to deliver strategy-based cognitive rehabilitation as an alternative to prevailing drill-based approaches, and 2) to integrate fatigue management to improve feasibility and acceptability of cognitive rehabilitation. This arm includes the cognitive rehabilitation only.
Study NCT06772558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Inhalation
Description: Anesthesia was maintained with either desflurane, with inhaled concentrations adjusted based on electroencephalogram (EEG) monitoring.
Study NCT06049901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses.
Study NCT06772558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane Inhalation
Description: Anesthesia was maintained with either desflurane, with inhaled concentrations adjusted based on electroencephalogram (EEG) monitoring.
Study NCT06772558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation (MV)
Description: Following induction, patients underwent mechanical ventilation in volume-controlled (VC) mode. Ventilation parameters were set using a GE Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA): tidal volume 6-8 ml/kg, positive end-expiratory pressure 0 cmH2O, inspiration/expiration ratio 1:2, respiratory rate 16 breaths/min, and inspired oxygen concentration of 41%.
Study NCT06772558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation (MV)
Description: Following induction, patients underwent mechanical ventilation in volume-controlled (VC) mode. Ventilation parameters were set using a GE Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA): tidal volume 6-8 ml/kg, positive end-expiratory pressure 0 cmH2O, inspiration/expiration ratio 1:2, respiratory rate 16 breaths/min, and inspired oxygen concentration of 41%.
Study NCT06772441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: * Goserelin: AstraZeneca, 10.8mg injection~* ADT will be applied for 12 months in total~* ADT must be given concurrently and adjuvant
Study NCT04870671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Description: Women will take 1 pill orally according the dosing regimen of the arm to which they are assigned
Study NCT06774846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid/Aspirin (100 mg)
Description: Patients will receive 100 mg acetylsalicylic acid (or Aspirin) orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.